Intellectual Property Policy Incoherence at the African Union Threatens Access to Medicines – Proposed Pan-African IP Organization a Terrible Idea
Image from Northeastern University School of Law Professor Brook K. Baker, Policy Analyst Health GAP September 26, 2012 In a stunning development, following an obscure vote of Heads of State at the Africa Union in 2007 (Assembly Council/AU/Dec. 138(VIII)), the AU Scientific, Technical, and Research Commission has proposed […]
Bayer’s attempt to block generic production of Sorafenib rejected; case on India’s first compulsory license still to be heard in court
Image from MSF Access Campaign Last week, the Intellectual Property Appellate Board of India rejected an attempt by the pharmaceutical company Bayer to stop the generic company Natco from producing a generic version of Sorafenib, used to treat liver and kidney cancer, while a court case over the country’s first compulsory license is deliberated.
The medical journal The Lancet has published an insightful summery of current legal challenges to India’s patent law. The authors argue that “pending cases against India’s patent laws threaten public health and misinterpret international intellectual property agreements”. This is also our view.
A tribute to the strength of sustained, global activism for affordable medicines Fire in the Blood trailer v3jul12 from Fire in the Blood on Vimeo. The 2012 film Fire in the Blood depicts the battle between HIV treatment activists (for access to affordable antiretroviral medicines) and the pharmaceutical industry (for the protection of their patents […]
Minister Motsoaledi made the keynote speech at the 6th Annual Conference on Competition Laws. In the speech he pointed to the success of measures to protect competition in improving access to HIV treatment and prevention in the country. His full speech can be found here